Feature | August 29, 2012| Dave Fornell

Bioresorbable Vascular Closure Devices Speed Ambulation

 An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure dev

An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure device, showing the attached PEG plug that had expanded into the tissue tract.

Vascular closure devices that use an active method to immediately seal the femoral access site can enable faster patient ambulation, reduce nursing time and speed discharge. However, one of the biggest issues interventionalists have with active vascular closure devices is the use of a permanent piece of hardware to stitch or clip the arteriotomy closed. Three companies now offer fully bioresorbable, active vascular closure devices, including a recent release earlier this year.  

In February 2012, the U.S. Food and Drug Administration (FDA) cleared AccessClosure’s new MynxGrip Vascular Closure Device (VCD). Built on the Mynx platform, the MynxGrip VCD adds the company’s patented Grip Technology sealant to the distal end of the original Mynx sealant, resulting in a better seal on the vessel and filling the tissue tract.

Hemostasis is achieved through the delivery of a water-soluble, bio-inert, non-thrombogenic polyethylene glycol (PEG) polymer on the shaft of a delivery catheter to the surface of the artery. The new formulation of PEG adheres better to the contours of the vessel wall. The material swells in size to fill the tissue tract. The sealant fully resorbs within 30 days. A 6 mm semi-compliant balloon is inflated against the arterial wall to establish temporary hemostasis during deployment of the sealant and ensures its extra-arterial placement. The result is an active seal that leaves no foreign material behind inside the vessel. 

Cordis Corp. gained FDA clearance for the Exoseal vascular closure device in May 2011. It incorporates an extravascular, bioabsorbable polyglycolic acid (PGA) plug. It is designed to close the femoral artery puncture site with minimal or no inflammation, is fully reabsorbed in 60-90 days. 

St. Jude Medical’s Angio-Seal line also offers a bioabsorbable active closure system. It includes use of an intra-arterial anchor attached to a suture and a collagen seal.

Related Content

nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
DMC Heart Hospital, Detroit Medical Center, complex percutaneous intervention education course, PCI, cath lab training
News | Cath Lab| August 22, 2016
The Detroit Medical Center (DMC) Heart Hospital recently completed a Complex Percutaneous Intervention education course...
TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant
News | Antiplatelet and Anticoagulation Therapies| August 18, 2016
Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored Antiplatelet Therapy...
Covidien, Medtronic, TurboHawk, Atherectomy system

The Medtronic TurboHawk atherectomy system. 

Feature | Atherectomy Devices| August 18, 2016 | Dave Fornell
Due to poor outcomes from percutaneous transluminal angioplasty (PTA) ballooning of vessels alone, or of stenting in
Sapien III, Sapien 3, PARTNER III, FDA approval, expanded indication, intermediate risk patients

The Sapien 3 valve has a skirt of fabric at its base that has significantly reduced issues of paravalvular leak, which was an issue with the first generation Sapien device. 

Feature | Heart Valve Technology| August 18, 2016 | Dave Fornell
August 18, 2016 — The U.S.
Corindus Corpath, Acist Medical RXi and CVi, Fairview Southdale Hospital, Minnesota, cath lab
News | Cath Lab| August 17, 2016
Corindus Vascular Robotics Inc. and Acist Medical Systems Inc. are providing Fairview Southdale Hospital, Edina, Minn...
Overlay Init